BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28883285)

  • 1. [Genetic abnormalities in core binding factor acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genomic landscape of core-binding factor acute myeloid leukemias.
    Faber ZJ; Chen X; Gedman AL; Boggs K; Cheng J; Ma J; Radtke I; Chao JR; Walsh MP; Song G; Andersson AK; Dang J; Dong L; Liu Y; Huether R; Cai Z; Mulder H; Wu G; Edmonson M; Rusch M; Qu C; Li Y; Vadodaria B; Wang J; Hedlund E; Cao X; Yergeau D; Nakitandwe J; Pounds SB; Shurtleff S; Fulton RS; Fulton LL; Easton J; Parganas E; Pui CH; Rubnitz JE; Ding L; Mardis ER; Wilson RK; Gruber TA; Mullighan CG; Schlenk RF; Paschka P; Döhner K; Döhner H; Bullinger L; Zhang J; Klco JM; Downing JR
    Nat Genet; 2016 Dec; 48(12):1551-1556. PubMed ID: 27798625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical mutatome of core binding factor leukemia.
    Opatz S; Bamopoulos SA; Metzeler KH; Herold T; Ksienzyk B; Bräundl K; Tschuri S; Vosberg S; Konstandin NP; Wang C; Hartmann L; Graf A; Krebs S; Blum H; Schneider S; Thiede C; Middeke JM; Stölzel F; Röllig C; Schetelig J; Ehninger G; Krämer A; Braess J; Görlich D; Sauerland MC; Berdel WE; Wörmann BJ; Hiddemann W; Spiekermann K; Bohlander SK; Greif PA
    Leukemia; 2020 Jun; 34(6):1553-1562. PubMed ID: 31896782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
    Mrózek K; Bloomfield CD
    J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
    Eisfeld AK; Kohlschmidt J; Schwind S; Nicolet D; Blachly JS; Orwick S; Shah C; Bainazar M; Kroll KW; Walker CJ; Carroll AJ; Powell BL; Stone RM; Kolitz JE; Baer MR; de la Chapelle A; Mrózek K; Byrd JC; Bloomfield CD
    Leukemia; 2017 Jun; 31(6):1278-1285. PubMed ID: 27843138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
    Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Core-binding factor acute myeloid leukemia.
    Sangle NA; Perkins SL
    Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual color FISH on CBF primary acute myeloid leukemia.
    Sorour A; Nafea D
    Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.
    Duployez N; Willekens C; Marceau-Renaut A; Boudry-Labis E; Preudhomme C
    Expert Rev Hematol; 2015 Feb; 8(1):43-56. PubMed ID: 25348871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
    Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
    Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
    Metzeler KH; Bloomfield CD
    Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
    Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
    Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
    Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
    Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.